Antibody response to human immunodeficiency virus after primary infection.
about
Structural insights on the role of antibodies in HIV-1 vaccine and therapyAIDS--A global perspective. Global epidemiology.Neuropathogenic SIVsmmFGb genetic diversity and selection-induced tissue-specific compartmentalization during chronic infection and temporal evolution of viral genes in lymphoid tissues and regions of the central nervous system.HIV incidence estimate combining HIV/AIDS surveillance, testing history information and HIV test to identify recent infections in Lazio, Italy.Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques.Superinfection of a chimpanzee with a second strain of human immunodeficiency virus.Immunofluorescence assay for detection of antibodies to human immunodeficiency virus type 2.Agreement study between two laboratories of immunofluorescence as a confirmatory test for human immunodeficiency virus type 1 antibody screeningNew sensitive and specific assay for human immunodeficiency virus antibodies using labeled recombinant fusion protein and time-resolved fluoroimmunoassay.Advantages of a human immunodeficiency virus type 1 (HIV-1) persistently infected HeLa T4+ cell line for HIV-1 indirect immunofluorescence serology.Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection.B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.A case of symptomatic primary HIV infection.Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design.Epstein-Barr virus and HIV play no direct role in persistent generalized lymphadenopathy syndrome.Neutralizing antibody and clinical status of human immunodeficiency virus (HIV)-infected individuals.Selecting an HIV Test: A Narrative Review for Clinicians and Researchers.Overproduction, purification, and diagnostic use of the recombinant HIV-1 Gag proteins, the precursor protein p55 and the processed products p17, p24, and p15.
P2860
Q26829461-4D115B21-D2A0-43A0-99D6-D2E0657C8697Q33615079-75AA0E55-C082-422C-A2EF-226F7E0A6BAEQ34100200-C2639422-0C29-4847-814B-97861BF5DB80Q34203609-0FFA8EFA-B43E-4A21-A5B1-E2CE2F4A9244Q34848486-F12F4416-74AE-4CEF-811C-C23DE5841B72Q36759774-F1959E1A-6471-49FF-A213-4459291972B7Q36920676-49C1F59E-6909-4813-8AFE-515B950AAF33Q37162406-6E763B31-4C41-4438-8A15-85906361BF33Q37174667-0A25FD56-CD8F-4B00-A4EA-23E1EA32DB6EQ37189070-35062138-CCC5-4559-B814-09B4B0E3D935Q37243778-CCFFEF5B-5A43-4D93-950E-AEF1FFE760B7Q40069582-7C06F254-8558-48D4-B764-DC2F78C8F9FEQ40130078-37BAE45C-A157-40C1-9584-37BF2E9A0D06Q40508063-DDE7603E-9CC9-4DDD-8648-9AC3BDB2EA65Q41338220-CF029C8F-9BC0-4735-AFD5-8B7A9D577986Q44168412-A6BFB2B0-A3BC-47EC-A790-0142AA633A03Q45843056-063103ED-D47A-45DD-9AA1-4B41843159E0Q48510061-7F4D1A0F-DF2A-48E4-98B3-F09467F487C7Q54619908-DF647A6E-6E01-4C8C-92C1-BC96EC998796
P2860
Antibody response to human immunodeficiency virus after primary infection.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Antibody response to human immunodeficiency virus after primary infection.
@en
Antibody response to human immunodeficiency virus after primary infection.
@nl
type
label
Antibody response to human immunodeficiency virus after primary infection.
@en
Antibody response to human immunodeficiency virus after primary infection.
@nl
prefLabel
Antibody response to human immunodeficiency virus after primary infection.
@en
Antibody response to human immunodeficiency virus after primary infection.
@nl
P2093
P356
P1476
Antibody response to human immunodeficiency virus after primary infection.
@en
P2093
P304
P356
10.1093/INFDIS/155.6.1113
P407
P577
1987-06-01T00:00:00Z